Sanara MedTech 将来の成長
Future 基準チェック /36
Sanara MedTech利益と収益がそれぞれ年間40.6%と11.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に17% 39.4%なると予測されています。
主要情報
40.6%
収益成長率
39.37%
EPS成長率
| Medical Equipment 収益成長 | 17.1% |
| 収益成長率 | 11.8% |
| 将来の株主資本利益率 | 17.00% |
| アナリストカバレッジ | Low |
| 最終更新日 | 30 Jul 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブ更新 • Jul 31
SMTI: MiMedx Deal Will Frame Future Upside And Downside Risk
Sanara MedTech's analyst fair value estimate has been adjusted from $36.00 to $32.00. Analysts point to the announced $35 per share acquisition by MiMedx and expectations for ongoing product and access expansion as key factors behind the updated price framework.分析記事 • Jul 30
Is There Now An Opportunity In Sanara MedTech Inc. (NASDAQ:SMTI)?
Sanara MedTech Inc. ( NASDAQ:SMTI ), might not be a large cap stock, but it saw a significant share price rise of 68...
ナラティブ更新 • Jul 06
SMTI: Future Soft Tissue Share Gains Will Support Bullish Outlook
Sanara MedTech's updated analyst fair value estimate has moved from $46.00 to $36.00, with analysts pointing to expectations for revenue growth of about 14.3%, a profit margin assumption of about 4.4%, and a future P/E of about 57.6x as key drivers of the revised target. Analyst Commentary Bullish analysts see Sanara MedTech as a company with room to execute on its surgical wound and soft tissue product portfolio, with fair value expectations framed around the updated revenue growth, margin, and P/E assumptions.
ナラティブ更新 • Jun 22
SMTI: Soft Tissue Share Gains And Portfolio Expansion Will Drive Future Upside
Sanara MedTech's updated analyst price target has edged up from about $34.00 to roughly $34.33 as analysts factor in expectations for higher revenue growth, a different profit margin profile and a higher future P/E, supported by recent bullish initiation reports highlighting potential from share gains, broader market access and portfolio expansion in surgical wound and soft tissue products. Analyst Commentary Recent research on Sanara MedTech points to a generally constructive view on the company, with analysts focusing on its role in surgical wound and soft tissue management and how that could influence future execution and valuation.ナラティブ更新 • Jun 07
SMTI: Cost Effectiveness Data And Bullish Initiation Will Drive Future Upside
Analysts now see fair value for Sanara MedTech holding at $34.00, supported by research that frames the stock through a slightly lower discount rate, steady revenue growth and profit margin expectations, and a marginally adjusted future P/E outlook. What's in the News Sanara MedTech issued earnings guidance for the second quarter of 2026, with expected net revenue in a range of $28.5 million to $29.5 million, compared with net revenue of $25.8 million for the same quarter a year earlier.ナラティブ更新 • May 21
SMTI: Cost Effectiveness Evidence Will Support Future Upside Under Bullish Initiation
Analysts have maintained their $34.00 price target on Sanara MedTech, pointing to slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that align with a recently initiated bullish view on the stock. Analyst Commentary Bullish Takeaways Bullish analysts point to the maintained US$34.00 target as consistent with their constructive view, seeing current assumptions on discount rate, revenue growth, profit margin and future P/E as reasonable within their framework.ナラティブ更新 • May 03
SMTI: Bullish Initiation And Cost Effectiveness Evidence Will Support Future Upside
Analysts have reaffirmed a $34.00 price target for Sanara MedTech, citing a fresh bullish initiation that highlights the company’s long term growth potential and supports unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed US$34.00 target as supported by the current fair value framework, with assumptions on discount rate, revenue growth, profit margin, and future P/E kept intact.ナラティブ更新 • Apr 19
SMTI: Bullish Coverage And Cost Effectiveness Study Will Support Future Upside
Analysts have reduced their price target on Sanara MedTech by $2 to $34. This reflects updated views on growth, profitability, and a higher assumed future P/E, following recent bullish Street initiation commentary.ナラティブ更新 • Mar 21
SMTI: Surgical Economics And Higher Margins Will Support Future Upside
Analysts have lowered their price target for Sanara MedTech from $40 to $36, citing revised fair value estimates, along with updated assumptions for revenue growth, profit margins, the discount rate and future P/E multiples. What's in the News A peer-reviewed study in the Journal of Medical Economics evaluates CellerateRX Surgical Powder as an add-on to standard care in high risk spinal surgery.ナラティブ更新 • Mar 05
SMTI: New Revenue Guidance And Surgical Pipeline Will Support Future Upside
Analysts have kept Sanara MedTech's fair value estimate steady at $40.00 per share, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E inputs that reflect fine tuning rather than a change in overall conviction. What's in the News Sanara MedTech issued new guidance for the fourth quarter of 2025, with expected net revenue between $27.2 million and $27.7 million.ナラティブ更新 • Feb 19
SMTI: Surgical Portfolio And Guidance Will Support Future Upside Potential
Analysts have maintained their $40.00 price target for Sanara MedTech, citing only very small adjustments to assumptions such as discount rate, long term revenue growth, profit margin and future P/E that did not materially change their overall valuation view. What's in the News Issued revenue guidance for Q4 2025, with expected net revenue in a range of $27.2 million to $27.7 million and commentary on the impact of approximately $1.8 million of BIASURGE sales in Q4 2024 on year over year comparisons (Corporate Guidance).ナラティブ更新 • Feb 04
SMTI: Core Surgical Focus Will Drive Future Upside Potential
Analysts have modestly adjusted their price target for Sanara MedTech to US$40.00. This reflects small updates to assumptions around discount rate, revenue growth, profit margin and future P/E that keep their overall valuation view essentially unchanged.ナラティブ更新 • Jan 21
SMTI: Core Surgical Focus And Orthopedic Alliance Will Drive Future Upside Potential
Analysts have trimmed their price target on Sanara MedTech from US$41 to US$40, reflecting updated assumptions around profit margins and future P/E expectations while keeping the overall long term growth story intact. What's in the News BIASURGE Advanced Surgical Solution received an Innovative Technology contract from Vizient Inc., signaling unique product qualities recognized by hospital experts on Vizient's client led councils (Key Developments).ナラティブ更新 • Jan 07
SMTI: Core Surgical Focus And Orthopedic Alliance Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Sanara MedTech steady at US$41.00. This reflects only small tweaks to their underlying assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock.ナラティブ更新 • Dec 14
SMTI: Core Surgical Focus Will Drive Future Profit Expansion And Upside Potential
Analysts have raised their price target for Sanara MedTech to approximately $41.00 per share, reflecting slightly lower discount rate assumptions and a marginally improved outlook for the company’s long term valuation multiples. What's in the News Sanara MedTech and Biomimetic Innovations provided an update on their strategic alliance focused on advancing orthopedic solutions and commercial readiness for new products (Key Developments).ナラティブ更新 • Nov 29
SMTI: Leadership Transition And Discontinued Operations Will Drive Profit Expansion Ahead
Analysts have reiterated their previous price target for Sanara MedTech at $41.00. They cite minimal changes in key financial assumptions and maintain a stable outlook for the company.ナラティブ更新 • Nov 15
SMTI: Leadership Transition And Streamlined Operations Will Drive Profitability Expansion
Narrative Update on Sanara MedTech: Analyst Price Target Revision Analysts have lowered their price target for Sanara MedTech from $50.00 to $41.00, citing updated estimates for key valuation metrics and a moderation in projected revenue growth. What's in the News Sanara MedTech is discontinuing operations of Tissue Health Plus (THP) to improve operating efficiency and will reclassify THP as discontinued operations in financial statements.分析記事 • Aug 13
Sanara MedTech Inc. (NASDAQ:SMTI) Doing What It Can To Lift Shares
With a median price-to-sales (or "P/S") ratio of close to 2.7x in the Medical Equipment industry in the United States...
新しいナラティブ • Mar 31
Tissue Health Plus And OsStic Will Expand Market Reach
Expansion in sales coverage and partnerships aims to boost product adoption, enhancing revenue in both new and existing markets.Seeking Alpha • Jan 30
Sanara MedTech: A Promising Growth Story At An Attractive Valuation
Summary Shares have risen nearly 15% since the company posted preliminary Q4 results, which showed revenue up by 45-48% year over year. While growth was boosted by one-off demand for its BIASURGE product, underlying growth was still strong at 37%. There remains a long runway for growth for its surgical products, with the potential for this to be augmented by other growth drivers, including inorganic opportunities. While the surgical segment is solidly profitable, overall profitability is depressed by losses in Sanara’s pre-commercialization segment. At 3 times revenue, I find the current valuation attractive, and hence I am assigning shares a Buy rating. Read the full article on Seeking Alpha分析記事 • Dec 19
Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 15
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results
Sanara MedTech Inc. ( NASDAQ:SMTI ) defied analyst predictions to release its quarterly results, which were ahead of...分析記事 • Sep 05
Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump
Sanara MedTech Inc. ( NASDAQ:SMTI ) shares have had a really impressive month, gaining 28% after a shaky period...分析記事 • Aug 14
Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • May 23
Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story
There wouldn't be many who think Sanara MedTech Inc.'s ( NASDAQ:SMTI ) price-to-sales (or "P/S") ratio of 3.8x is worth...分析記事 • Nov 15
Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • May 22
Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)
You may think that with a price-to-sales (or "P/S") ratio of 5.8x Sanara MedTech Inc. ( NASDAQ:SMTI ) is a stock to...分析記事 • Mar 22
Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results
Sanara MedTech Inc. ( NASDAQ:SMTI ) last week reported its latest annual results, which makes it a good time for...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 152 | 6 | 10 | 12 | 1 |
| 12/31/2027 | 133 | 5 | 10 | 13 | 2 |
| 12/31/2026 | 118 | 2 | 11 | 9 | 3 |
| 3/31/2026 | 107 | 1 | 3 | 6 | N/A |
| 12/31/2025 | 103 | 0 | 2 | 7 | N/A |
| 9/30/2025 | 102 | -1 | -1 | 4 | N/A |
| 6/30/2025 | 97 | 1 | 0 | 4 | N/A |
| 3/31/2025 | 92 | -1 | -2 | 0 | N/A |
| 12/31/2024 | 87 | -2 | 0 | 0 | N/A |
| 9/30/2024 | 78 | -3 | -2 | -2 | N/A |
| 6/30/2024 | 72 | -7 | -3 | -3 | N/A |
| 3/31/2024 | 68 | -5 | -3 | -3 | N/A |
| 12/31/2023 | 65 | -4 | -4 | -3 | N/A |
| 9/30/2023 | 63 | -8 | -3 | -3 | N/A |
| 6/30/2023 | 60 | -9 | -4 | -6 | N/A |
| 3/31/2023 | 54 | -6 | -6 | -5 | N/A |
| 12/31/2022 | 46 | -8 | -6 | -6 | N/A |
| 9/30/2022 | 38 | -7 | -8 | -7 | N/A |
| 6/30/2022 | 30 | -8 | -9 | -6 | N/A |
| 3/31/2022 | 27 | -10 | -6 | -6 | N/A |
| 12/31/2021 | 24 | -8 | -6 | -5 | N/A |
| 9/30/2021 | 22 | -5 | -5 | -4 | N/A |
| 6/30/2021 | 20 | -4 | -3 | -3 | N/A |
| 3/31/2021 | 17 | -4 | -4 | -3 | N/A |
| 12/31/2020 | 16 | -4 | -6 | -4 | N/A |
| 9/30/2020 | 14 | -6 | -6 | -4 | N/A |
| 6/30/2020 | 13 | -5 | -6 | -4 | N/A |
| 3/31/2020 | 13 | -4 | -6 | -4 | N/A |
| 12/31/2019 | 12 | -3 | N/A | -2 | N/A |
| 9/30/2019 | 11 | -1 | N/A | -1 | N/A |
| 6/30/2019 | 10 | 0 | N/A | -1 | N/A |
| 3/31/2019 | 9 | 0 | N/A | 0 | N/A |
| 12/31/2018 | 9 | 0 | N/A | 1 | N/A |
| 9/30/2018 | 8 | 0 | N/A | 1 | N/A |
| 6/30/2018 | 7 | 0 | N/A | 0 | N/A |
| 3/31/2018 | 7 | 0 | N/A | 0 | N/A |
| 12/31/2017 | 6 | 0 | N/A | 0 | N/A |
| 9/30/2017 | 6 | 0 | N/A | 0 | N/A |
| 6/30/2017 | 6 | 0 | N/A | 1 | N/A |
| 3/31/2017 | 6 | -1 | N/A | 0 | N/A |
| 12/31/2016 | 6 | -1 | N/A | 0 | N/A |
| 9/30/2016 | 4 | -1 | N/A | 0 | N/A |
| 6/30/2016 | 4 | -2 | N/A | -1 | N/A |
| 3/31/2016 | 3 | -1 | N/A | -1 | N/A |
| 12/31/2015 | 3 | -2 | N/A | -1 | N/A |
| 9/30/2015 | 3 | -1 | N/A | -1 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: SMTIの予測収益成長率 (年間40.6% ) は 貯蓄率 ( 3.7% ) を上回っています。
収益対市場: SMTIの収益 ( 40.6% ) はUS市場 ( 17.1% ) よりも速いペースで成長すると予測されています。
高成長収益: SMTIの収益は今後 3 年間で 大幅に 増加すると予想されています。
収益対市場: SMTIの収益 ( 11.8% ) US市場 ( 13% ) よりも低い成長が予測されています。
高い収益成長: SMTIの収益 ( 11.8% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: SMTIの 自己資本利益率 は、3年後には低くなると予測されています ( 17 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/09 18:47 |
| 終値 | 2026/08/07 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Sanara MedTech Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Yi Chen | H.C. Wainwright & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |